Phase 2 ProHear Study Reaches 50% Patient Enrollment
Acousia Therapeutics' ProHear Study is evaluating ACOU085 for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy.
Acousia Therapeutics' ProHear Study is evaluating ACOU085 for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy.
Lenire is sponsoring the 10th Annual Hearoes Tour to expand access to hearing and tinnitus care for U.S. veterans through free nationwide screenings and support.
Knowing the auditory, vestibular, and cognitive issues associated with chronic illnesses can help hearing care professionals better treat patients with these conditions.
Investigational gene therapy DB-OTO showed promising improvements in hearing and speech development in children with otoferlin-related genetic hearing loss.
Researchers have identified and mapped diverse cell types in the cochlear nucleus, a critical part of the auditory system, advancing understanding of how our brains process sounds and paving the way for targeted treatments for auditory disorders.
Neuromod Devices Ltd. has secured €10 million in oversubscribed equity financing to expand the availability of its FDA-approved tinnitus treatment device, Lenire.
Audiology Australia’s "Min-Max Your Hearing" campaign aims to promote safer listening practices, especially among people who play video games.
A new study reveals that auditory stimuli significantly impact balance in individuals with vestibular hypofunction.
Henry Schein is donating essential healthcare products to be used for athlete health screenings at the 2025 Special Olympics World Winter Games in Turin, Italy.